Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays ...
GenomOncology and Genomenon Partner to Enhance Germline Variant Classification and Genomic Reporting
CLEVELAND, Nov. 7, 2024 /PRNewswire/ -- GenomOncology, an a precision medicine software company, and Genomenon, a leading genomic intelligence company, today announced a strategic partnership aimed at ...
The genetic confirmation of a suspected diagnosis of "hereditary colorectal cancer" is of great importance for the medical care of affected families. However, many of the variants identified in the ...
SAN FRANCISCO, March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with Clinical Variant Modeling, a ...
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma Next-generation sequencing ...
Please provide your email address to receive an email when new articles are posted on . Researchers assigned clinical classifications to thousands of BRCA2 variants of uncertain significance. Research ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today presented an important study at the 2016 American College of Medical Genetics and Genomics (ACMG) ...
Lightweight convolutional neural networks improved lung cancer classification accuracy in histopathological images while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results